Phenylephrine

證據等級: L5

預測適應症: 3 個

Phenylephrine: From Sympathomimetic Vasopressor to Nasal Cavity Disease

One-Sentence Summary

Phenylephrine is a selective α1-adrenergic receptor agonist with established global use as a nasal decongestant and vasopressor, though it currently holds no registered product license in the Philippines. The TxGNN model predicts it may be effective for Nasal Cavity Disease, with 8 clinical trials and 8 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	No Philippines registration; globally recognized as nasal decongestant and vasopressor
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.97%
Evidence Level	L2
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data from the DrugBank record was not available for this evaluation. Based on established pharmacology, Phenylephrine is a highly selective α1-adrenergic receptor agonist. It acts directly on vascular smooth muscle α1-receptors in the nasal mucosa, inducing vasoconstriction, which reduces mucosal engorgement and swelling and restores nasal airway patency. This represents the classical pharmacological mechanism of topical nasal decongestants and is mechanistically well-differentiated from non-selective sympathomimetics such as ephedrine.

The link between this mechanism and nasal cavity disease is direct and well-characterized: phenylephrine-containing combination products—Co-phenylcaine (phenylephrine + lidocaine) and Polydexa (phenylephrine + neomycin + polymyxin B + dexamethasone)—are routinely used in ENT clinical practice for nasal mucosal preparation prior to endoscopic procedures and for treatment of acute rhinosinusitis. These applications address a spectrum of inflammatory and obstructive nasal cavity conditions.

The TxGNN score of 99.97% reflects this well-established α1-agonist–nasal mucosa pharmacological axis. The fact that phenylephrine is not currently registered in the Philippines, despite its global clinical footprint in ENT products, represents a regulatory gap rather than a scientific one. Its inclusion in multi-component nasal preparations widely used in clinical contexts relevant to nasal cavity disease further supports the reasonableness of this prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03380715	N/A	Completed	106	Directly evaluated Co-phenylcaine nasal spray (containing phenylephrine) vs. nebulization prior to rigid nasoendoscopy; assessed decongestion quality, local anaesthetic effect, and patient comfort
NCT00562120	Phase 2	Completed	21	Randomised, double-blind, placebo-controlled 4-way crossover study evaluating an H3 receptor antagonist vs. placebo for nasal congestion in seasonal allergic rhinitis; acoustic rhinometry used to quantify congestion relief
NCT06443255	Phase 3	Completed	16	Triple crossover trial comparing cocaine, lidocaine/xylometazoline, and saline for intranasal analgesia and decongestion prior to awake nasotracheal intubation
NCT03228914	Phase 4	Completed	20	Compared topical oxymetazoline vs. epinephrine (mechanistically analogous α-agonists) for reducing intraoperative blood loss and optimising surgical field during endoscopic sinus surgery
NCT06457100	Phase 1/2	Active, Not Recruiting	60	Compared esmolol vs. lidocaine infusions for postoperative recovery quality in functional endoscopic sinus surgery (FESS); phenylephrine employed as background haemodynamic agent
NCT02993770	N/A	Unknown	120	Compared endonasal-endoscopic vs. external dacryocystorhinostomy; phenylephrine used as standard pre-operative nasal mucosal preparation
NCT04104789	Phase 2	Withdrawn	0	Planned comparison of Kovanaze nasal mist vs. articaine for maxillary dental pulpal anaesthesia; withdrawn prior to any enrolment
NCT03962634	Phase 2	Terminated	3	Comparison of Kovanaze vs. articaine for dental pulpal anaesthesia; terminated early after only 3 participants enrolled

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15854186	2005	RCT	Int J Clinical Practice	Double-blind RCT (n=98): Cophenylcaine nasal spray (containing phenylephrine) vs. placebo before flexible nasendoscopy; assessed pain, taste discomfort, and overall tolerability
40899890	2025	Clinical Trial	Vestnik Otorinolaringologii	Experimental and clinical evaluation of Polydexa spray with phenylephrine in acute rhinosinusitis; demonstrated safety profile and clinical efficacy of topical phenylephrine-containing combination therapy
25133491	2014	RCT	PLoS ONE	Triple-blind RCT evaluating topical tranexamic acid vs. placebo in FESS for chronic rhinosinusitis; provides clinical context for surgical field management in nasal cavity procedures
37184554	2023	Clinical Study / Review	Vestnik Otorinolaringologii	Endoscopic assessment of nasal mucosal status following Polydexa nasal spray with phenylephrine in chronic nasal cavity diseases and granulomatosis with polyangiitis
37970776	2023	Review	Vestnik Otorinolaringologii	Pathogenetic review of inflammatory diseases of the nose and paranasal sinuses; discusses role of vasoconstriction in reducing hyperaemia and oedema, supporting use of phenylephrine-containing formulations
9780066	1998	Cohort	Int J Pediatric Otorhinolaryngology	Acoustic rhinometry evaluated nasal cavity and nasopharyngeal geometry before and after adenoidectomy/tonsillectomy; characterises turbinate changes relevant to nasal cavity disease assessment
7378007	1980	Case Report	Arch Ophthalmology	Reports adverse reactions to intranasal phenylephrine (Neo-Synephrine) during dacryocystorhinostomy; highlights risk of sympathomimetic potentiation when co-administered with cocaine
1375136	1992	In Vitro	Clinical Otolaryngology	Investigated the effect of drugs used in nasal disease treatment, including phenylephrine, on ciliary beat frequency; documented a dose-dependent suppressive response

Philippines Market Information

Phenylephrine currently has no registered product licenses in the Philippines. No authorisations or approved products are on record with the Philippines FDA.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The pharmacological basis for phenylephrine in nasal cavity disease is well-established through decades of global ENT clinical practice, supported by multiple completed clinical trials involving phenylephrine-containing products and a near-perfect TxGNN prediction score of 99.97%. The absence of a Philippines market registration reflects a regulatory gap rather than a scientific or clinical deficiency.

To proceed, the following is needed:

Retrieve Philippines FDA (FDA-PH) package insert or equivalent safety documentation to resolve the blocking data gap on key warnings and contraindications (DG001)
Confirm full mechanism of action data via DrugBank API query (DG002)
Determine appropriate dosage form and route of administration strategy for the Philippines market (intranasal topical vs. systemic formulations)
Review pharmacovigilance data for reported adverse events in comparable Southeast Asian populations
Initiate Philippines FDA registration assessment pathway, given the current zero-licence status but strong global evidence base
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.